Gordon Parry, Ph.D. has been promoted to the position of vice president, R&D, oncology, Monogram Biosciences, Inc. Dr. Parry will have responsibility for the company’s oncology research and development programs, including the further development of Monogram’s VeraTag technology platform and the first product based on that platform, the HERMark Breast Cancer Assay. He will continue to manage the oncology R&D team.

Dr. Parry joined the company in 2007 as senior director of R&D, oncology. Prior to joining the company, he worked for 12 years at Berlex Biosciences where he was the department head of the cancer research department. Previously, he held a variety of research positions in academia, including ten years at the University of California ‘s Lawrence Berkeley Laboratory. He is currently an Advisory Council Member for the California Breast Cancer Research Program.         

“Gordon has a tremendous experience base in the development of cancer therapeutics and has already contributed significantly to the development of our VeraTag platform,” said William Young, Monogram’s chief executive officer. “HERMark, our first product, is currently the subject of studies to establish its clinical utility in breast cancer and I am pleased to have someone of Gordon’s experience and talent working on the further enhancement of the VeraTag technology platform and the expansion of our portfolio of assays, both in breast and other cancers.”